Top Clean Energy Stocks To Own For 2019

Call it global warming. Call it climate change. Maybe it’s a nuance, or maybe your political stance determines how you feel about this debate. 24/7 Wall St. has tracked investment in clean energy and renewable energy for years.

It turns out that 2016 broke the growth cycle for investing in clean energy — and then some.

With a new Trump administration about to take office, it looks like there is a night and day views on climate change versus the Obama administration. That makes this report something which likely cannot be ignored. After all, it was only known for less than two months that Hillary Clinton’s clean energy trends would not continue what was seen under the Obama administration. Still, it’s a big world and many other nations outside of the United States havea seriousrole in clean energy.

The news at the start of 2017 is showing a stark difference for 2016. Bloomberg New Energy Finance now shows that the total dollars of new investments into clean energy fell a whopping 18% down to $287.5 billion in 2016. While the prior year was a record of $348.5 billion, what stands out here now is that the 2016 figure is also represented as being 9% lower than the $315 billion invested into clean energy in 2014.

Top Clean Energy Stocks To Own For 2019: Haverty Furniture Companies, Inc.(HVT)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Havertys (NYSE:HVT) – Stock analysts at KeyCorp dropped their Q2 2018 earnings per share estimates for Havertys in a research report issued on Wednesday, May 2nd. KeyCorp analyst B. Thomas now anticipates that the company will post earnings per share of $0.29 for the quarter, down from their previous forecast of $0.31. KeyCorp also issued estimates for Havertys’ Q3 2018 earnings at $0.39 EPS and Q4 2018 earnings at $0.45 EPS.

Top Clean Energy Stocks To Own For 2019: Ionis Pharmaceuticals, Inc.(IONS)

Advisors’ Opinion:

  • [By Brian Orelli]

    Pfizer (NYSE:PFE) threw Alnylam and fellow ATTR drugmaker Ionis Pharmaceuticals (NASDAQ:IONS) a curveball in March, releasing positive results from a trial testing its ATTR drug tafamidis in patients with ATTR cardiomyopathy. But Alnylam isn’t backing down with potential plans to run a trial comparing its next-generation TTR drug, ALN-TTRsc02, against tafamidis, as outlined by Akshay Vaishnaw, Alnylam’s executive vice president of research and development:

  • [By Brian Orelli]

    Ionis Pharmaceuticals (NASDAQ:IONS), Akcea’s majority ownerand the developer of Waylivra, is up 4.4% on the news as well.

    So what

    A 12-8 vote isn’t exactly a ringing endorsement, but it was pretty clear from the FDA documentsfor the committee, which were publicly posted on Tuesday, that the agency reviewers were torn between the efficacy and safety of Waylivra, which also goes by the generic name volanesorsen. Patients with FCS have elevated levels of triglycerides (TG), which Waylivra clearly helps reduce, but the drug is also associated with thrombocytopenia, or low blood platelet levels.

  • [By Chris Lange]

    Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings reportfrom partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was releasedfor IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.

  • [By George Budwell]

    Biogen’s top-line growth has now become almost totally dependent on sales of its fairly new spinal muscular atrophy (SMA) drug, Spinraza, that it co-developed with Ionis Pharmaceuticals (NASDAQ:IONS).

Top Clean Energy Stocks To Own For 2019: iShares MSCI EAFE (EFA)

Advisors’ Opinion:

  • [By Stephan Byrd]

    SimpliFi Inc. lifted its position in iShares MSCI EAFE ETF (NYSEARCA:EFA) by 0.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 156,749 shares of the exchange traded fund’s stock after purchasing an additional 967 shares during the quarter. iShares MSCI EAFE ETF accounts for about 9.0% of SimpliFi Inc.’s holdings, making the stock its 6th largest holding. SimpliFi Inc.’s holdings in iShares MSCI EAFE ETF were worth $10,922,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Smart Portfolios LLC acquired a new stake in shares of iShares MSCI EAFE ETF (NYSEARCA:EFA) during the 1st quarter, reports. The fund acquired 2,906 shares of the exchange traded fund’s stock, valued at approximately $202,000.

  • [By Todd Shriber, ETF Professor]

    HEFA debuted in early 2014 as the currency hedged alternative to traditional MSCI EAFE strategies. HEFA is essentially the MSCI EAFE ETF (NYSE: EFA) with a currency hedged kicker. EFA, one of the largest developed market ETFs, is HEFA lone equity holding. HEFA has amassed $3.61 billion in assets since coming to market.